Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases

Pedro Acién1,3*, Maribel Acién1,3, Eva Ruiz-Maciá1,3 and Carlos Martín-Estefanía2

Abstract

The association of ovarian teratoma and anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a serious and potentially fatal pathology that occurs in young women and that is under-recognized. Our objectives were to analyze prevalence and outcome of this association, and increase awareness over this pathology. MEDLINE and SCOPUS for all studies published prior to November 30, 2013 including the search terms: "encephalitis" and "teratoma" were considered. All articles (119) reporting one or more cases of anti-NMDAR encephalitis and confirmed ovarian teratoma (174 cases) were included. No language restrictions were applied. Suspicious cases with no evidence of ovarian teratoma (n = 40) and another type of encephalitis also associated to ovarian teratoma (n = 20) were also considered for comparison and discussion. Data of publication and case report, surgery and outcome were collected. The distribution of published cases is heterogeneous among different countries and continents, probably in relation with level of development and health care. The mean patient age is 24 years and in the majority of cases (74%), a mature teratoma was identified, sometimes microscopically following ovarian removal or at autopsy. The clinical presentation featured psychiatric symptoms and behavioural changes, with a median delay for surgery of 28 days. Twelve women died (7%), most frequently from encephalitis-related complications. In conclusion, the association ovarian teratoma and anti-NMDAR encephalitis is relatively unknown or not reported in many countries and among gynecologists. Heightened recognition of behavioral changes, diagnosis through transvaginal ultrasound and subsequent tumor removal in addition to diagnostic confirmation through the presence of anti-NMDAR antibodies must be emphasized.

Keywords: Anti-NMDAR encephalitis, Anti-NMDA-Receptor antibodies, Dermoid cyst, Limbic encephalitis, Ovarian teratoma

Additional non-English language abstract (Spanish)

La asociación de teratoma ovárico y encefalitis anti-NMDAR es una patología grave y potencialmente mortal, poco conocida y que ocurre en mujeres jóvenes. El objetivo de esta revisión sistemática fue analizar la prevalencia y el devenir de esta asociación, así como llamar la atención sobre el necesario conocimiento de esta patología. Fueron considerados todos los estudios encontrados en MEDLINE y SCOPUS, empleando los términos de búsqueda "encefalitis" y “teratoma”, hasta el 30 de Noviembre de 2013; y fueron incluidos en la revisión todos los artículos (119) que reportaban uno o mas casos de encefalitis anti-N-methyl-D-aspartate receptor (NMDAR) con teratoma ovárico confirmado (174 casos). No hubo restricciones por idioma. Los casos sospechosos pero sin demostrar el teratoma ovárico (n = 40), así como otros tipos de encefalitis también asociados a teratoma (n = 20), fueron (Continued on next page)
Introduction

Limbic encephalitis was initially described as a paraneoplastic syndrome characterized by the rapid development of confusion and personality changes, irritability, depression, seizures, short-term memory loss, sometimes dementia and high MRI T2 and FLAIR signal intensity involving one or both medial temporal lobes [1]. It was primarily associated with lung or testicular cancer and with antibodies against intracellular neuronal antigens [2]. However, recently a new type of encephalitis was described in women with ovarian teratoma and antibodies [2].

In fact, Vitaliani et al. [3] and Dalmau et al. [4] described a disorder that appeared to represent a new subcategory of severe and potentially lethal, yet treatment-responsive, paraneoplastic encephalitis, which they described as “paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma”.

The affected patients were women who developed prominent psychiatric symptoms, seizures, memory deficits and a decreased level of consciousness that often required ventilatory support. Three salient features of the syndrome included the young patient age, the association with ovarian teratoma and the detection of antibodies to unknown antigens that were predominantly expressed in the cell membranes of hippocampal neurons (neuropil antigens) [6].

All of the studies described above were performed by a group headed by J. Dalmau (Department of Neurology, University of Pennsylvania, PA, USA) that reviewed previously reported cases in 2007, along with eight additional patients in whom they identified the target autoantigens as heteromers containing NR1 and NR2 subunits of the NMDA receptor that were expressed by the associated tumors [4]. This syndrome is now referred to as anti-NMDAR encephalitis, and although it was initially associated with ovarian teratoma in women, it has now been described in men and is increasingly being recognized in children [7,8]. However, gynecologists may not be aware of this serious and potentially fatal pathologic condition that frequently originates in the ovary.

Objectives

This review discusses the incidence and prevalence, country of origin, histological type of ovarian teratoma and outcome of the teratoma-associated anti-NMDAR encephalitis and provides practical guidance for the general gynecologist, thus contributing to the diffusion of knowledge regarding this association that, notwithstanding its clinical infrequency, has the potential for severe consequences.

Methods for review

Sources

A comprehensive search of PubMed and SCOPUS was performed for all studies published prior to November 30, 2013, using the search terms “encephalitis” and “teratoma”, which yielded 192 articles in PubMed and 274 in SCOPUS. A systematic review of these papers was performed, and after removal of repeated articles from both searches and cases involving male patients, the titles and abstracts of all articles were evaluated to determine whether case reports with ovarian teratoma were included. There were no language restrictions, although for articles in Chinese or Japanese, only abstracts were consulted.

Study selection

All publications reporting one or more cases with encephalitis and ovarian teratoma, including suspicious cases in which the tumor had not been found, were selected for...
review and full publication analysis. Altogether, 119 reports containing a total of 173 cases of anti-NMDAR encephalitis and ovarian teratoma were identified from 1997 until November 30, 2013. To these, we have added our case attended in 2012–2013 and recently published [9], making a total of 174 cases of ovarian teratoma-associated anti-NMDAR encephalitis.

Moreover, 7 of the aforementioned papers and another 32 papers published between 2009 and 2013 described 40 additional cases of anti-NMDAR encephalitis and suspicious of teratoma in which, following ultrasound, CT or MR, an ovarian teratoma had not been found. Other 11 pediatric cases (seven in females) of anti-NMDAR encephalitis without teratoma [8], and 20 female cases of ovarian teratoma with brainstem-cerebellar manifestation with or without opsoclonus-myoclonus syndrome reported by Armangue et al. [10] (including three cases previously reported [11-13]) have also been analyzed or independently commented on. Flow diagram for the study is shown in Figure 1 as supplemental data.

The following data were collected from all of the articles containing any case of anti-NMDAR encephalitis and ovarian teratoma: authors, journal and year of publication, country of birth or hospital service where the case was studied, number of cases included with or without ovarian tumor, patient age, clinical presentation, type of ovarian teratoma, tumor size and laterality, medical treatment, time to surgery, surgery performed, outcome and time to recovery. These data were tabulated in a Supplemental Data File (Additional file 1: Table S1), and were also entered into SPSS statistics (IBM, Spain) and statistically analyzed. Times to discharge, partial recovery or full recovery were considered following the case reported if it was mentioned.

We also analyzed the case series of anti-NMDAR encephalitis, with or without teratoma, in which the cases were not individually reported, and the most comprehensive reviews of paraneoplastic limbic encephalitis for discussion.

Statistical analysis

Data were introduced in a SPSS-15 file being statistically analyzed. Percentages, mean and standard deviation, and median with minimal and maximal values were obtained. Comparison of independent means (Student’s T-test), comparison of two proportions (relative risk –RR-) , a 95% confidence interval (CI) and the chi-squared test were used to compare the groups. RSigma (Systat Software, San Jose, California, USA) and PEDro (Physiotherapy Evidence Database, Sidney, Australia) software were also used. All p values reported are 2 tailed and p value of 0.05 or less was considered significant.

Results

174 cases of anti-NMDAR encephalitis caused by ovarian teratoma have been studied and analyzed (see Additional file 1: Table S1 at Supplementary Data).

The publication years for cases of anti-NMDAR encephalitis and ovarian teratoma are presented in Table 1A. It is notable that the number of papers and case reports has progressively increased since the 2007 publication of Dalmau et al. [4]. Most articles containing case reports

![Figure 1 Flow diagram for the systematic review.](http://www.ojrd.com/content/9/1/157)
have been published in neurology or psychiatry journals, with only 11% of studies published in gynecologic journals, including those in gynecologic oncology (Table 1B). With regard to the country of birth (or eventually, the country of study), as shown in Table 1C, a global imbalance exists that can likely be attributed, at least in part, to differences in the level of development and health care. Except for a Mauritanian patient who was attended in France [14], not a single case has been reported from Africa. In Asia, only one case each has been published from China and India, whereas Japan has reported 38 cases. No cases have been reported from Russia. In the Americas, three cases have been reported from Central and South America, whereas the USA has contributed 47 cases. In addition, 14 cases have been described in papers from Spain and the USA by the Dalmau group, without specification of individual case origin [15,16].

In Table 2, the mean age (with standard deviation and median), tumor laterality, size and histological type are presented. Most published cases with anti-NMDAR encephalitis were associated with mature teratomas (dermoid cysts) (57% overall, or 74% in the subgroup of cases where the histologic type was specified), and 29 (16.7% overall, or 21.6% among the cases where histological type was specified) were immature teratomas. Certain cases manifested both types of teratoma or demonstrated immature teratoma foci (3.4%); however, in 40 cases (23%) the histological type was not reported. The mean age was similar in all groups with teratoma (23.9 ± 7.8 years; median 24 years) but was significantly lower in cases where a teratoma was not found (19.1 ± 9.8 years; median 17 years).

The tumor was located more frequently on the right ovary, but differences were not significative. Immature teratomas or mature teratomas with immature foci were larger (9–11 cm) than dermoid cysts, although it should be noted that in some cases, the teratoma was microscopic and was only found following oophorectomy [17] or at autopsy [18] several months after admission.

The clinical presentation in the majority of cases was similar to our case [9], particularly with regard to the memory impairment, psychiatric symptoms and behavioral changes, and also included psychosis, abnormal movements of the face, mouth and tongue, fever, headache, hallucinations, rhinorrhea, hypersalivation, seizures, catatonia and status epilepticus. Two affected patients also presented during pregnancy [19]. An important finding in this systematic review was the extended time lapse between hospitalization and diagnosis or surgical removal of the tumor. Many patients had been admitted to different hospitals, often psychiatric, or departments other than gynecology prior to undergoing surgery. The median time to surgery was 28 days, with a range between 2 and 455 days. Because in most cases it was not suspected that the encephalitis was caused by teratoma, the mean time to surgery was 28 days, with a range between 2 and 455 days. In 20 cases of ovarian teratoma with brainstem-cerebellar manifestation with or without opsoclonus-myoclonus syndrome (a novel treatment-responsive encephalitis negative for anti-NMDAR antibodies [10]), the median age was 28.5 years; among them, there was only one case of immature teratoma and in 13 cases of mature teratoma. In the pediatric series of anti-NMDAR encephalitis without teratoma, the mean age was 6.9 years (range 2.5–12.9 years).

Table 1 Year of publication, journal and country of birth or study of patients with anti-NMDAR encephalitis and ovarian teratoma

| 1A. Year of publication (number of papers) | Number of cases | %   |
|------------------------------------------|-----------------|-----|
| Before/or in 2006 (13)                   | 16              | 9.2 |
| 2007 (6)                                 | 14              | 8.1 |
| 2008 (11)                                | 18              | 10.4|
| 2009 (14)                                | 17              | 9.8 |
| 2010 (18)                                | 21              | 12.1|
| 2011 (21)                                | 27              | 15.6|
| 2012 (18)                                | 27              | 15.6|
| 2013 (November 30) (18)                 | 33              | 19.1|
| TOTAL (119)                              | 173             | 100 |

| 1B. Journal of publication | Number of cases | %   |
|----------------------------|-----------------|-----|
| 1. Neurology or Psychiatry | 86              | 49.7|
| 2. Internal or general medicine | 34          | 19.6|
| 3. Other Specialties       | 34              | 19.6|
| 4. Gynecological, included Oncological Gynecology | 19 | 11.0 |
| TOTAL                      | 173             | 100 |

| 1C. Country of birth or study | Number of cases | %   |
|------------------------------|-----------------|-----|
| Africa, Mauritania (France)  | 1               | 0.6 |
| Asia, Japan-Taiwan-Singapore-Hong Kong-China-S-Korea-Lebanon | 51 | 29.5 |
| Australia, New Zeland      | 13              | 7.5 |
| Europe, Spain-UK-France-Germany-Netherlands-Italy-Turkey-Ireland-Greece | 39 | 22.5 |
| North-America, USA-Canada-Mexico | 52 | 30.1 |
| Center and South-America    | 3               | 1.7 |
| Spain-Barcelona v USA       | 14              | 8.1 |
| TOTAL                       | 173             | 100 |

The most frequent surgical procedure for mature teratoma removal was simple tumor excision while uni/bilateral salpingo-oophorectomy and radical surgery was reserved for patients with immature teratomas. A few isolated cases achieved recovery without tumor removal, whereas in 6 women (3.4%), the tumor was found...
at autopsy. Cases of recurrent dermoid cyst and recurrent encephalitis have been reported [20], whereas other patients have presented with encephalitis months or years following removal of the ovarian teratoma [21]. In contrast, the tumor was only found after a period of slow recovery from encephalitis [22] in some patients who also had negative test results in earlier diagnostic methods.

The diagnostic workup based on the definitive determination of anti-NMDAR antibodies in blood or preferably in cerebrospinal fluid (CSF) [23], and the imaging of ovarian teratoma were similar to those in our case [9]: abdomino-pelvic CT image and transvaginal ultrasound (TVU). The medical treatments were also similar and included acyclovir, methylprednisolone, ivIg, anticonvulsants and chemotherapy in cases of immature teratoma. Other effective therapies included plasmapheresis and antiepileptic and anticonvulsive therapy, with some cases requiring tracheostomy or gastrostomy.

The patient outcomes according to the teratoma histological type are shown in Table 4. A full recovery was achieved by 88% of women with mature teratoma and 76% of women with immature teratoma after several months or years. The mean time to acceptable recovery and hospital discharge was 3.6 ± 3.3 months (median 3 months; range 0.5–24 months). Permanent sequelae were observed in 11.5% of patients, and 12 women expired (7%) from encephalitis-related complications that did not depend on the histological type of teratoma.

In the 40 women with anti-NMDAR encephalitis in whom an ovarian teratoma was not found, 85% achieved a full recovery however, the time to recovery was longer (6.3 ± 4.1 months; median 5.5 months; range 1–14 months) than in patients whose ovarian teratomas were removed. In addition, three patients (7.5%) achieved only a partial recovery, and one patient died [24]. Similarly, only 50% of pediatric patients without teratoma experienced a full recovery [8], and two patients had severe residual sequelae. Among the patients with brainstem-cerebellar syndrome and teratoma [10], 74% experienced a full recovery, 16% had partial improvement, and two patients had no improvement (one of whom did not undergo surgery).

Table 2 Age of patients, histological type of ovarian teratoma, laterality of the affected ovary and tumor size

| Variable                        | Histological type of ovarian teratoma | Total of cases with teratoma | Ovarian teratoma not found |
|---------------------------------|--------------------------------------|------------------------------|----------------------------|
| Age (N)                         | Mature (99)                           | 144                          | 264                        |
| Mean ± SD                       | 24.1 ± 7.3                           | 24.9 ± 8.4                   | 26.0 ± 10.0                |
| Median(min-max)                 | 24(7–42)                             | 25(9–41)                     | 26(15–39)                  |
| Tumor location                  |                                      |                              |                            |
| Right ovary                     | 34(60.7)                             | 13(23.2)                     | 21(3.6)                    |
| Left ovary                      | 34(73.9)                             | 11(23.0)                     | 0-                         |
| Bilateral                       | 10(50.0)                             | 2(10.0)                      | 3(15.0)                    |
| Not marked                      | 21(40.4)                             | 3(5.8)                       | 1(1.9)                     |
| Total                           | 99(56.9)                             | 29(16.7)                     | 6(3.4)                     |
| Teratoma size(cm)               |                                      |                              |                            |
| Mean ± SD(N)                    | 5.7 ± 5.7(61)                        | 9.0 ± 5.0(20)                | 11.2 ± 5.9(5)              |
| Median(m-m)                     | 4(0.1–22)                            | 7(2.5–22)                    | 11(5–20)                   |

* p < 0.001 versus cases with teratoma (CI 1.96-7.64).

Table 3 Time to diagnosis and surgery (days) and surgery performed according to teratoma histological type

| Histological type (N) | Time to diagnosis/surgery (N), median mean ± SD | Surgery performed | Autopsy N (%) |
|-----------------------|-----------------------------------------------|-------------------|---------------|
|                       | Time to diagnosis/surgery | Tumor excision N (%) | Unilateral adnexectomy N (%) | Bilateral cystectomy N (%) | Bilat. Ooph. or radical N (%) | No surgery N (%) |
| Mature (99)           | (85), 39 days 71.4 ± 88.5^*                   | 54(54.5)^*        | 34(34.3)       | 5(5.1)                     | 2(2.0)                      | 1(1.0)          | 3(3.1)         |
| Immature (29)         | (26), 27.5 days 39.4 ± 28.6^*                 | 8(27.6)           | 17(58.6)       | 0-                          | 4(13.8)                     | 0-              | 0-             |
| Mature + Immature (6) | (3), 14 days 140.0 ± 0.0                      | 0-                | 2(33.3)        | 0-                          | 3(50.0)                     | 1(16.7)         | 0-             |
| Not specified (40)    | (10), 13.5 days 37.3 ± 42.5                   | 25(62.5)          | 5(12.5)        | 1(2.5)                     | 3(7.5)                      | 3(7.5)          | 3(7.5)         |
| Total (174)           | (124), 28(3–455) days 60.6 ± 77.0            | 87(50.0)          | 58(33.3)       | 6(3.4)                     | 12(6.8)                     | 5(2.9)          | 6(3.4)         |

* T test, p < 0.02 (CI 3–67); ^* Chi² test, p < 0.05, RR = 1.97 (CI 1.1-3.6); ***, RR = 1.7 (1.1-2.57).
We have included in the systematic review all detailed cases of ovarian teratoma-associated anti-NMDAR encephalitis appearing in PubMed and/or Scopus and whose data had been reported as individual case report. Observational cohorts' studies without individual description of cases have not been included in the analysis of cases.

Weaknesses
1. We suspect that this pathological association is underdiagnosed and infrareported. Moreover, the case has not been analyzed if the publishing journal is not in PubMed or Scopus. 2. Teratoma is not always found, especially among girls and adolescents. 3. There may be extraovarian teratoma. 4. The ovarian teratoma may also cause a novel type of encephalitis negative for anti-NMDAR, with brainstem-cerebellar manifestation and with or without opsoclonus-myoclonus syndrome [10].

Main findings
The association of anti-NMDAR encephalitis and ovarian teratoma is a severe, prolonged and potentially fatal pathologic condition of young women that has been increasingly reported in developed countries since its identification and publication by Dalmau et al. [4]. But is uncommon in girls ≤14 years of age [25], Only 4 females younger than 12 years ~6%- had a tumor in Titulaer et al. [26] study.

The most frequent clinical presentations are neuropsychiatric symptoms (especially, behavioural changes), although the neuropsychiatric manifestations may often be preceded by nonspecific prodromal symptoms. Moreover, the typical presentation of the cases include memory impairment and, later but very evocative, abnormal movements of the face, mouth and tongue and symptoms of dysautonomia. General practitioners and gynecologists should be cognizant of available imaging modalities that may be employed in the early stage and of the need for the eventual discovery of a dermoid cyst because early tumor resection with immunotherapy will facilitate patient recovery. It should also be noted that at the onset of symptoms, the results of anti-NMDA antibody testing may be negative, even in CSF [21]. Nevertheless, it has been suggested that in some patients with anti-NMDAR encephalitis the antibodies were detectable only in the CSF [27]; and Gresa-Arribas et al. [23] have reported that the sensitivity of NMDA receptor antibody testing is higher in CSF than in serum, that the titres were higher in patients with poor outcome and that antibody titres can complement clinical assessment.

Interpretation and alternative explanations for observed results
Even small ovarian teratomas containing nervous tissue may express NMDAR subunits that react with a patient's antibodies, thereby triggering a cascade of symptoms that is recognized as anti-NMDAR encephalitis and that mainly affects the hippocampus/forebrain regions. In such cases, tumor resection and immunotherapy result in improvement or full recovery. However, the diagnosis is difficult and time-consuming, and patients may succumb to neurological deterioration, thus necessitating a high index of suspicion and prompt intervention, even in the absence of confirmatory studies.

From this systematic review, it is apparent that awareness of the association of ovarian teratoma (usually benign or dermoid cyst) and anti-NMDAR encephalitis is low in many parts of the world, possibly because practitioners may not entertain such a diagnosis, thus resulting in a low rate of diagnosis even among affected patients. Some women may be transferred from one hospital to another or from one service to another, which may contribute to the fatality rate of approximately 7%, with the teratoma occasionally found only at autopsy. Therefore, heightened awareness will benefit patients through a more rapid identification of this association, especially in Africa, Asia and Central and South America, and particularly among gynecologists. Few reported cases have emerged from these regions, possibly because of their respective levels of health care and socio-economic development.

Table 4 Outcome of anti-NMDAR encephalitis patients with or without ovarian teratoma

| Histological type of teratoma | OUTCOME | Recovery N (%) | Partial recovery N (%) | Died N (%) | Time to discharge or partial recovery (N, median (m-m)) m ± SD (months) |
|-------------------------------|---------|----------------|-----------------------|-----------|-------------------------------------------------|
| Mature (99)                   | 87(87,9)| 8(8,1)         | 4(4,0)                | (47), 3(0,5-12), 3,1 ± 2,0 |
| Immature (29)                 | 22(75,9)| 5(17,2)        | 2(6,9)                | (9), 3(0,7-11), 4,3 ± 3,4 |
| Mature + Immature (6)         | 4(66,7)| 1(16,7)        | 1(16,7)               | (3), 4(3–6–), 4,3 ± 1,5  |
| Not specified (40)            | 29(72,5)| 6(15,0)        | 5(12,5)               | (11), 3(1–24), 5,0 ± 6,4 |
| Total with teratoma (174)     | 142(81,6)| 20(11,5)      | 12(6,9)               | (70), 3(0,5-24), 3,6 ± 3,2 |
| Ovarian teratoma not found (40)| 34(85)*| 3(7,5)         | 1(2,5)                | (10), 5,5(1–14), 5,7 ± 3,7* |

(N), n° of cases in which this variable is known; *, not documented in two cases.
* CI 1,0-4,25 versus mature teratoma.
However, from the point of view of ethnicity, Titulaer et al. [26] in a cohort multi-institutional observational study of 577 anti-NMDAR encephalitis patients have observed that Asian and African-American patients were more likely to have a teratoma (45% and 48% respectively) than Caucasian (31%) or Hispanics (27%), being \( p < 0.007 \).

On the other hand, Tachivana et al. [28] noted that in the vast majority of encephalitis cases, patients have a prodromal infection before the onset of the disease. Should this infection affect either the normal ovary or ovarian teratoma, it may trigger the expression of NMDAR-related epitopes in oocytes and lead to the development of limbic encephalitis disease [29]. Indeed, ovarian teratomas that contain large amounts of neural tissue may present an increased risk for the development of this type of life-threatening encephalitis. Subsequently, the diagnosis can be established by identification of anti-NMDA antibodies in the serum and CSF. When these antibodies are positive, even in the absence of teratoma, it has been suggested that proceeding to exploratory laparotomy may increase the possibility of identifying microscopic teratoma and may improve the outcome in patients who are refractory to immunotherapy [30], however it is unclear whether this procedure is the most appropriate.

**Generalization of the conclusions**
It now appears relevant to raise the questions posed to gynecologists by the 2009 report of Kort et al. [31].

**Incidence and prevalence of this condition**
Only eight cases with paraneoplastic limbic encephalitis and teratoma, some of which were recurrent [20], were described before 2005, the year in which Dalmau et al. introduced the determination of anti-NMDAR antibodies in the serum and CSF [3,6,32]. Since 2007, the year in which Dalmau et al. published their work in the Annals of Neurology [4], there has been a progressive increase in the number of articles and case reports regarding this entity. Thus, it appears that the incidence of this condition is higher than previously estimated and will continue to increase with improvements in health care, knowledge of the condition and improved socioeconomic development, especially in many of the larger countries of Asia, Africa and South-America where cases have not yet been reported. General practitioners and gynecologists should be aware that the underlying cause of anti-NMDAR encephalitis may involve a simple ovarian dermoid cyst.

**Clinical presentation**
Neuropsychiatric symptoms, rapid neurological deterioration, ICU admission and ventilator support are often initiated before the diagnosis is established. Patients often require long periods of support, and they may also develop tracheotomy complications related to hypersalivation and may develop life-threatening hyperthermia before teratoma-associated encephalitis is even suspected. Other frequent prodromal symptoms are, e.g., earache, headache, dysuria and malaise, which may be attributed to various benign etiologies. Although it is not common practice to perform a gynecological examination at the time of catatonia or status epilepticus, if an X-ray, CT, MR or ultrasound demonstrates ovarian pathology or calcification, it is imperative to consider the association of ovarian teratoma and encephalitis.

**Diagnosis**
Serum and CSF evaluation for anti-NMDAR antibodies and imaging tests, particularly transvaginal or transrectal ultrasound in female patients to identify small ovarian teratomas, are essential for diagnosis. In cases of brainstem cerebellar syndrome with or without teratoma-associated opsoclonus-myoclonus syndrome, anti-NMDAR antibody studies may be negative [10].

**Treatment**
The combination of tumor removal and immunotherapy (ivlg, corticosteroids and plasma exchange) yields the best therapeutic results and a more rapid recovery than immunotherapy alone [4]. In the cohort study of Titulaer et al. [26] it was observed that patients without a tumor had a higher frequency of relapses than those with a tumor. Therefore, tumor resection should be performed as soon as possible after psychomotor and hemodynamic stabilization of the patient. In some cases, a delay in tumor excision has led to death [4,33], although other patients have recovered without surgery [34]. Boeck et al. [17] performed ovarectomy despite negative imaging in anti-NMDAR encephalitis. Histological examination revealed an occult teratoma and they pointed out that removal of the teratoma even 11 months after a very severe course is still therapeutically effective.

**Role of the dermoid cyst and need for its excision**
Regardless of the histological type (most mature teratomas), teratomas exhibit elements of the three blastodermic layers and contain neural tissue that triggers an immune response resulting in over-production of anti-NMDAR antibodies. Dalmau et al. [35] demonstrated that all dermoid tumors examined in anti-NMDAR encephalitis patients contained neural tissue, and 100% of specimens tested were positive for NMDA receptors. Similarly, it was noted that the presence of NR2B immunoreactivity in normal human ovary oocytes may account for the occurrence of anti-NMDAR encephalitis in predominantly young females and its absence in girls [28,29]. In a case [36], a bilateral
oophorectomy was performed despite the absence of a teratoma on imaging tests after the patient had failed to recover from anti-NMDA encephalitis over a 6-week period. Histology demonstrated a small, 0.7 cm mature teratoma and patient recovered afterwards. Thus, if all imaging tests are negative, it has been recommended to proceed with exploratory laparotomy and a large wedge resection of the ovary to increase the likelihood of microscopic teratoma identification and to improve the outcome in patients who are refractory to immunotherapy and have anti-NMDAR antibodies [17,30], but this issue remains controversial. We believe that a focused transvaginal or transrectal ultrasound may help decision-making better than a wedge resection, and if results are negative, all immunotherapeutic protocols should be used before proceeding to bilateral salpingoopherectomy that could result in ovaries macroscopically identifiable and patient recovered afterwards. Thus, if all imaging tests follow by diagnosis through TVU and subsequent tumor removal in addition to diagnostic confirmation through the presence of anti-NMDAR antibodies in teratoma patients is not indicated.

**Guidelines for future research**

Heightened recognition of behavioral changes as the initial symptoms of this entity must be emphasized, followed by diagnosis through TVU and subsequent tumor removal in addition to diagnostic confirmation through the presence of anti-NMDAR antibodies. However, in some cases, the teratoma could present following the encephalitis or be microscopic. Besides, some patients with ovarian teratoma may develop other forms of encephalitides that are not anti-NMDAR-related [10] or have extra-ovarian teratomas, notably mediastinal teratomas [40,41]. These aspects should guide future investigation among encephalitis and teratoma.

**Conclusions**

The association ovarian teratoma-anti-NMDA encephalitis is a serious and potentially fatal pathology occurring in young women and under-recognized in many countries and among gynecologists.

Heightened recognition of cognitive and behavioral changes, diagnosis through TVU and subsequent tumor removal in addition to diagnostic confirmation through the presence of anti-NMDAR antibodies must be emphasized.

**Additional file**

**Additional file 1: Table S1.** Reported cases of anti-NMDAR encephalitis and ovarian teratoma.

**Abbreviations**

CT: Computed tomography; ICU: Intensive care unit; GP: General practitioner; X-ray: Radiography; MR: Magnetic resonance; TVU: Transvaginal ultrasound.

**Competing interests**

We declare that we have no competing interests.

**Author information**

Obstetrics and Gynecology and Neurology Services, San Juan University Hospital. Department/Division of Gynecology, Miguel Hernández University, Campus of San Juan, Alicante, Spain.

**Authors’ contributions**

PA designed the study, made the review and figures, and wrote the manuscript. MA and ERM made the literature search and reviewed the manuscript. CME attended to patient and reviewed the manuscript. PA had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

**Acknowledgements**

American Journal Experts edited the manuscript for proper English.

**Source of the work or study**

Systematic review of the literature.

**Author details**

1. Obstetrics and Gynecology Service, San Juan University Hospital, Alicante, Spain.
2. Neurology, San Juan University Hospital, Alicante, Spain.
3. Department/Division of Gynecology, Miguel Hernández University, San Juan Campus, 03550 Alicante, Spain.

Received: 16 September 2014 Accepted: 1 October 2014

Published online: 14 October 2014

**References**

1. Gulütekin SH. Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000; 123(Pt 7):1481–1494.

2. Graus F, Saiz A. Limbic encephalitis: an expanding concept. Neurology 2008, 70(7):500–501.

3. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hyperventilation in ovarian teratoma. Ann Neurol 2005, 58(4):594–604.

4. Dalmau J, Tituzin E, Wu HY, Majumdar J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61(1):25–36.

5. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevs Smitt PA, Tanasuciu R, Vedeler CA, Voltz R, Verschuuren JJ, European Federation of Neurological Societies. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011, 18(1):19–e3.

6. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005, 128(Pt 8):1764–1777.

7. Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr 2010, 22(6):739–744.

8. Pérez E, Ruggieri V, Monges S, Loos M, Caraballo R, Rugilo C, Vincent A, Arcayo HA. Encephalitis aguda mediada por anticuerpos contra el receptor ionotrópico de glutamate activado por N-methyl-D-aspartato (NMDAR):
analysis of de once casos pediatricos en Argentina. Medicina (Buenos Aires) 2013, 73:1–9.

9. Acién P, Ruiz-Macía E, Acién M, Martín-Estefania C. Mature ovarian teratoma-associated limbic encephalitis. J Obstet Gynaecol 2014, 34:1–2.

10. Armangue T, Titulaer MJ, Sabater L, Pardo-Moreno J, Gresa-Aribas N, Barbero-Bordallo N, Kelley GR, Kyung-Ha N, Takeda A, Nagao T, Takahashi Y, Lucano A, Carr AS, Graus F, Dalmau J. A novel treatment-responsive encephalitis with frequent opsonolus and teratoma. Ann Neurosc Larry 2014, 75:435–441.

11. Fitzpatrick AS, Gray OM, McConville J, McDonnell GV: Anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. Ann J Obstet Gynecol 2011, 205:464–468.

12. Tanyi JL, Marshall BA, Dalmau J, Chu CS: Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. Acta Obstet Gynecol Scand 2011, 91(1):530–534.

13. Kayser MS, Titulaer MJ, Gresa-Aribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-Methyl-D-Aspartate receptor encephalitis. JAMA Neurol 2013, 70(9):1133–1139.

14. Boeck A, Logemann F, Krauss T, Hussein K, Bultmann E, Trebst C, Stangel M: Ovarectomy despite negative imaging in anti-NMDA receptor encephalitis: effective even late. Case Rep Neurol Med 2013, 2013:84192.

15. Liu S, Kai J, Fuchigami H: Update on anti-NMDA receptor encephalitis (article in Japanese). Brain Res 2010, 12(1):331–338.

16. Kumar MA, Jain A, Dechant VE, Saito T, Nagaoka N, Takahashi Y, Fukuda K, Graus F, Dalmau J. Anti-N-methyl-D-aspartate receptor encephalitis in a young girl with an immature ovarian teratoma. Brain Nerve 2010, 117(2):382–384.

17. Kawachi I, Saji E, Toyoshima Y, Dalmau J, Nishizawa M: Treatment responsive opsonolus-ataxia associated with ovarian teratoma. J Neuro Neurosurg Psychiatry 2010, 81(5):581–582.

18. Naoura I, Didelot A, Walker F, Luton D, Koskas M: Anti-N-methyl-D-aspartate receptor encephalitis complicating ovarian teratomas: a case report. Ann J Obstet Gynecol 2011, 205:464–468.

19. Teny JL, Marsh BA, Dalmau J, Chu CS: Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. Acta Obstet Gynecol Scand 2011, 91(1):530–534.

20. Kort DH, Valliere AM, DeMarco EF, Lobo RA: Paraneoplastic anti-N-methyl-D-aspartate-receptor encephalitis from mature cystic teratoma. Obstet Gynecol 2009, 114(2):373–376.

21. Stein-Westler R, Wootton-Gorges SL, Greco CM, Brunberg JA: Paraneoplastic limbic encephalitis in a teenage girl with an immature ovarian teratoma. Pediatr Radiol 2005, 35(7):694–697.

22. Estrada HMR, Torres MIA, Reyes CMM, Rivera ZD: Encefalitis limítica y síndrome neuroléptico maligno secundario a teratoma óvarico maduro con componente inmaduro. Comunicación de un caso fatal y revisión de la bibliografía. Patol Latinoam 2011, 49(4):276–282.

23. Shindo A, Kagawa K, II, Sasaki R, Kuboku Y, Kuzuhara S: Anti-N-methyl-D-aspartate receptor-related grave but reversible encephalitis with ovarian teratoma in 2 Japanese women presenting with excellent recovery without tumour resection. Eur Neurol 2009, 61(1):50–51.

24. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SS, Rosenfeld MR, Ballenger G, Lynch DR: Anti-NMMA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7(12):1091–1098.

25. Dabner M, McCullage WG, Bundell C, Carr A, Leung Y, Sharma R, Stewar CJ: Ovarian teratoma associated with anti-N-methyl-D-aspartate receptor encephalitis: a report of 5 cases documenting prominent intratumoral lymphoid infiltrations. Int J Gynecol Pathol 2012, 31(5):429–437.

26. Khadem GW, Hebbe S, Kumar R, White C: Anti-N-methyl-D-aspartate receptor antibody limbic encephalitis. Intern Med J 2009, 39(1):54–56.

27. Parratt KL, Allan M, Lewis SJ, Dalmau J, Halmagyi GM, Spies JM: Acute psychiatric illness in a young woman: an unusual form of encephalitis. Pediatr Neurol 2008, 39(1):84–88.

28. Mangler M, Trebesch De Perez I, Trenget B, Stöcker W, Speiser D: Seroprevalence of anti-N-methyl-D-aspartate receptor antibodies in women with ovarian teratoma. J Neurol 2013, 260(11):2831–2835.

29. Stover DG, Eisenberg R, Johnson DH: Anti-N-methyl-D-aspartate receptor encephalitis in a young woman with a mature mediastinal teratoma. J Thorac Oncol 2010, 5(11):1972–1973.

30. Kawahara K, Miyawaki M, Anami K, Moroga T, Yamamoto S, Tokuishi K, Yamashita S, Kumamoto T: A patient with mediastinal mature teratoma presenting with paraneoplastic limbic encephalitis. J Thorac Oncol 2012, 7(12):258–259.

Cite this article as: Acién et al.: Ovarian teratoma-associated anti-NMDA receptor encephalitis: a systematic review of reported cases. Orphanet Journal of Rare Diseases 2014 9:157.